ACLARION INC Stock Price, News & Analysis

Aclarion (NASDAQ: ACON) announced the appointment of Jason Brosniak as Commercial Director, Eastern U.S., effective Dec 2, 2025.

Brosniak brings 20+ years in commercial roles at MedTech firms including Relievant Medsystems, Kyphon, and Intrinsic Therapeutics and will lead adoption and payer engagement for Nociscan across the densely populated Eastern U.S. The hire follows recent UK commercial expansion and coincides with growing demand from real-world evidence trials and the national CLARITY randomized controlled trial.

Nociscan is described as a SaaS platform that noninvasively quantifies chemical biomarkers to help distinguish painful versus nonpainful lumbar discs.

Aclarion (Nasdaq: ACON, ACONW) appointed Dan Isherwood as UK Commercial Director to accelerate adoption of its Nociscan solution in the UK market.

The company said Nociscan is now reimbursed by three of the top four UK private insurers, covering more than 5.2 million lives, and has early integration at a leading London spine clinic. Isherwood brings imaging and spine commercial experience from J&J MedTech, EOS Imaging, and NuVasive and earlier NHS clinical experience.

Aclarion (Nasdaq: ACON) was named a Rising Star in the Clinical Diagnostic Device category at the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH on October 22, 2025.

The award, chosen from more than 1,800 submissions, recognizes Aclarion's Nociscan SaaS platform, which uses MR spectroscopy and proprietary AI to generate objective biomarkers to help physicians distinguish painful from non-painful lumbar discs. The company said the technology aims to improve personalized treatment decisions for chronic low back pain, a condition affecting an estimated 266 million people worldwide.

Aclarion (Nasdaq: ACON) issued a Q3 2025 corporate update highlighting accelerating commercial adoption, a strong cash position, and progress in its pivotal CLARITY trial.

Key facts: Nociscan scan volumes +89% YoY in Q3 with three consecutive record quarters; debt-free balance sheet with $13.3 million cash (≈$15.11/share) as of Oct 14, 2025; CLARITY enrolling with first patients at University of Miami and full enrollment targeted by Q4 2026; early 3-month interim readouts expected Q2 2026. Company appointed Greg Gould as CFO and will present at LD Micro on Oct 20, 2025.

Aclarion (Nasdaq: ACON) participated in the International Society of Pain and Neuroscience Annual Meeting in London on Oct 13, 2025, where a session co‑moderated by Doug Beall, M.D., highlighted the role of MR Spectroscopy and Aclarion’s Nociscan in identifying biomarkers of discogenic low back pain.

Nociscan is described as a SaaS platform that converts MR spectroscopy signals into objective biomarkers to help differentiate painful vs non‑painful lumbar discs and inform personalized treatment decisions. The company emphasized multidisciplinary clinical engagement and insurer approval at a UK clinic for study access.

Aclarion (Nasdaq: ACON) was named a finalist on Oct 7, 2025 for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH in the Rising Star - Clinical Diagnostic Device category.

Nociscan is described as a SaaS platform that transforms MR spectroscopy signals into objective biomarkers to noninvasively distinguish painful from non-painful lumbar discs, supporting more personalized treatment plans. The company cites an estimated 266 million people worldwide living with chronic low back pain and notes it was selected from more than 1,800 submissions.

Aclarion (NASDAQ:ACON) presented at LSI Europe '25, showcasing its Nociscan platform that combines MR spectroscopy with AI to identify chronic low back pain sources. The technology helps physicians differentiate between painful and non-painful lumbar discs, enabling more targeted treatment plans.

The company highlighted its ongoing 300-patient CLARITY randomized clinical trial, which aims to demonstrate improved surgical outcomes beyond the current 54% industry success rate. Interim results are expected in Q2 2026. The company also noted its strengthened balance sheet position to support commercial and clinical initiatives.

Aclarion (NASDAQ:ACON) has announced the enrollment of its first two patients at UHealth – University of Miami Health System in the pivotal CLARITY trial for its Nociscan technology. The study will evaluate Nociscan's effectiveness in improving surgical outcomes for chronic low back pain patients.

The CLARITY trial will enroll 300 patients across multiple US sites, with patients randomized in a 1:1 ratio between surgeons blinded and unblinded to Nociscan results. The trial's primary endpoint is measuring change in back pain at 12 months post-surgery, with interim results expected in Q2 2026.

Nociscan is the first evidence-supported SaaS platform that helps physicians identify painful discs in the lumbar spine through MR Spectroscopy and AI technology, addressing a condition affecting approximately 266 million people globally.

Aclarion (NASDAQ: ACON) has appointed Greg Gould as its new Chief Financial Officer, effective immediately. Gould brings over 30 years of experience and succeeds retiring CFO John Lorbiecki. Throughout his career, Gould has raised more than $450 million in public company financing, led over ten acquisitions, and successfully guided three companies through Nasdaq uplistings.

Most recently serving as CFO at Nanos Health, Gould's extensive experience includes CFO roles at seven publicly-traded companies, including Charlotte's Web and Aytu BioScience. His appointment comes at a crucial time as Aclarion continues to expand the availability of its Nociscan solution, which helps physicians identify painful discs in patients with chronic low back pain.